Reversible Chemical Modification of Antibody Effector Function Mitigates Unwanted Systemic Immune Activation

Philip N. Moquist,Xinqun Zhang,Chris I. Leiske,Nicole M.-L. Eng-Duncan,Weiping Zeng,Noah A. Bindman,Serena W. Wo,Abbie Wong,Clark M. Henderson,Karalyne Crowder,Robert Lyon,Svetlana O. Doronina,Peter D. Senter,Haley D. Neff-LaFord,Django Sussman,Shyra J. Gardai,Matthew R. Levengood

DOI: https://doi.org/10.1021/acs.bioconjchem.4c00212

IF: 4.7

2024-05-26

Bioconjugate Chemistry

Abstract:Antibody effector functions including antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) are mediated through the interaction of the antibody Fc region with Fcγ receptors present on immune cells. Several approaches have been used to modulate antibody Fc-Fcγ interactions with the goal of driving an effective antitumor immune response, including Fc point mutations and glycan modifications. However, robust antibody-Fcγ engagement and immune cell binding of Fc-enhanced...

chemistry, multidisciplinary,biochemistry & molecular biology, organic,biochemical research methods

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to reduce adverse reactions caused by systemic immune activation while enhancing antibody effector functions to improve anti - tumor immune responses. Specifically, the paper explores a method of reversibly regulating antibody effector functions through chemical modification, aiming to balance effective anti - tumor activity and reduce the risk of systemic immune activation. This method utilizes a simple polyethylene glycol (PEG) linker conjugated to the inter - chain disulfide bond of the antibody via a maleimide linkage. This method can weaken the binding of the antibody to Fcγ receptors in the early stage of administration, thereby reducing systemic cytokine release and other dose - limiting infusion - related reactions, and at the same time restoring the function of the antibody in vivo over time to achieve anti - tumor effects.

### Key Point Summary:

1. **Problem Background**:
- Antibody effector functions (such as ADCC and ADCP) are mediated by the interaction between the antibody Fc region and Fcγ receptors on immune cells.
- Enhancing the Fc - Fcγ receptor interaction can improve anti - tumor immune responses, but excessive immune cell binding may lead to systemic cytokine release and other adverse reactions.
- Balancing effective anti - tumor activity and avoiding systemic immune activation is an ongoing challenge.

2. **Solution**:
- A method of reversibly regulating antibody - Fcγ receptor interactions through chemical modification has been developed.
- Use a polyethylene glycol (PEG) linker conjugated to the inter - chain disulfide bond of the antibody via a maleimide linkage.
- This method weakens the binding of the antibody to Fcγ receptors in the early stage of administration, reduces systemic immune activation, and then gradually restores the function of the antibody in vivo.

3. **Experimental Verification**:
- The effectiveness of this method has been verified through in vitro and in vivo experiments.
- The experimental results show that PEG - modified antibodies significantly reduce Fc - induced immune activation in vitro and in mice and non - human primates, while retaining anti - tumor activity and improving pharmacokinetic properties.

4. **Potential Applications**:
- This simple, modular system can be quickly applied to other antibodies that cause systemic immune activation due to Fcγ receptor binding.
- This technology is expected to improve the tolerance of immune agonists and the safety of clinical applications.

### Conclusion:
This study provides a new strategy to reversibly regulate the effector functions of antibodies through chemical modification, thereby reducing the risk of systemic immune activation while maintaining anti - tumor activity. This provides new ideas for the development of safer and more effective immunotherapy antibodies.